Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
April 7, 2020
Assignee:
IMMODULON THERAPEUTICS LIMITED
Inventors:
Charles Akle, John Grange, Kevin Bilyard
Abstract: An immunomodulator is for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably includes a whole cell Mycobacterium, such as M. vaccae or M. obuense.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
April 7, 2020
Assignee:
IMMODULON THERAPEUTICS LIMITED
Inventors:
Charles Akle, John Grange, Kevin Bilyard
Abstract: Herein is provided a method that provides a patient, suspected of having Lyme disease, a kit that does not require specialized equipment and allows for easy self-collection of specimens. Methods provided herein, allow for the efficient culturing of Borrelia spirochetes, such as B. burgdorferi spirochetes after being exposed to an environment that is typically not suitable for Borrelia growth.
Abstract: Disclosed are methods of detecting the presence of Loa loa in a biological sample using one or more antigens, each having a different amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20. Related compositions, specific binding partners, and test kits are also disclosed.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
March 24, 2020
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Thomas B. Nutman, Sasisekhar Bennuru, Papa Makhktar Drame
Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
Type:
Grant
Filed:
January 15, 2016
Date of Patent:
March 24, 2020
Assignee:
The Johns Hopkins University
Inventors:
John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, and RRSP). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency.
Type:
Grant
Filed:
November 30, 2017
Date of Patent:
March 24, 2020
Assignee:
THE HOSPITAL FOR SICK CHILDREN
Inventors:
Roman A. Melnyk, Anick Auger, Greg Beilhartz, Berge Minassian, Seiji Sugiman-Marangos
Abstract: Provided are a fusion protein of a pneumococcal surface adhesin A (PsaA) and a pneumococcal surface protein A (PspA), and preparation method and use thereof. Also provide are a nucleic acid for encoding the protein, carrier and cell for expressing the protein, and vaccine composition comprising the protein.
Type:
Grant
Filed:
March 29, 2016
Date of Patent:
March 17, 2020
Assignees:
Changchun BCHT Biotechnology Co., Jilin University
Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
March 17, 2020
Assignee:
The Rockefeller University
Inventors:
Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
Abstract: Non-invasive methods are provided herein for diagnosing samples as including a fungus, including fungal infection or contamination, with specific monoclonal antibodies capable of detecting molecules associated with fungi in the sample, such as a biological or environmental sample. These molecules can be identified using various methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), or a lateral flow immunoassay.
Type:
Grant
Filed:
April 23, 2016
Date of Patent:
March 10, 2020
Assignee:
Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
Inventors:
Thomas R. Kozel, Breeana Hubbard, Amanda Burnham-Marusich
Abstract: The invention provides a bioactive peptide including a partial amino acid sequence of Plasmodium falciparum enolase, and having a molecular structure compatible with a specification setting for a GMP-compliant production process. The peptide has a structure in which two peptides, each having an amino acid sequence of A01-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-A02 (SEQ ID NO: 1) or A03-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-Lys-Ser-Leu-Val-Lys-Thr-A04 (SEQ ID NO: 2) are linked by amide bonds between the respective carboxy termini of the two peptides and two amino groups of Lys in a linker peptide represented by Lys-A05-Cys-A06 and arranged in the form of a two-forked branch, wherein each of A01 to A06 represents an amino acid residue in a number of an arbitrary number including 0.
Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
March 3, 2020
Assignee:
The Secretary of State for Environment, Food and Rural Affairs
Inventors:
Hans Martin Vordermeier, Benjamin Sidders, Neil Graham Stoker, Katie Ewer
Abstract: Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.
Abstract: The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.
Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
February 11, 2020
Assignee:
MedImmune Limited
Inventors:
Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
Abstract: A method for preparing a protein isolate of the biomass of microalgae of the genus Chlorella, includes the following steps: supplying a microalgal biomass produced by fermentation, washing the biomass so as to eliminate the soluble interstitial compounds and concentrating the biomass, mechanically grinding the washed and concentrated biomass in a horizontal ball grinder-type system in order to produce an emulsion, destructuring the emulsion thus produced, triple-phase separation so as to separate the soluble fraction from the fractions containing the lipids and the cell debris, recovery of the soluble fraction thus produced in order to produce the soluble protein isolate, then evaporation, pasteurization and atomization of the protein isolate.
Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum), The invention is based on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
December 31, 2019
Assignee:
STATENS SERUM INSTITUT
Inventors:
Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
Abstract: Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
December 17, 2019
Assignee:
Vedanta Biosciences, Inc.
Inventors:
Rose L. Szabady, Bernat Olle, Bruce Roberts
Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
Type:
Grant
Filed:
September 17, 2018
Date of Patent:
December 10, 2019
Assignees:
Leidos, Inc., The U.S. of America, as represented by the Secretary, Dept. of Health and Human Services
Inventors:
Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
Abstract: The objective of the present invention is to provide a peptide of which both of binding forces to a Fc region and a Fab region are superior. In addition, the objective of the present invention is to provide a DNA which encodes the peptide, a vector which contains the DNA, and a transformant which is transformed by the vector. The problem can be solved by providing the peptide having the specific sequence.